Assessing patient-centered outcomes in rare diseases is essential for understanding treatment benefit. However, patient heterogeneity introduces an extra layer of complexity in assessing outcomes. We have expertise in identifying concepts and developing endpoint strategies for rare heterogenous diseases, leveraging expertise from COA consulting, clinical development, and health economics and outcomes research.
Our expertise in consulting and the pharmaceutical industry, encompassing clinical development, regulatory, and commercial functions,...
Client Testimonials
"HAIKO LLC's expertise in patient-centric consulting has truly transformed our approach for participants engagement and retention at Alliance Research Institute. Their strategies are innovative and impactful, making a real difference in our clinical trials."
Victor Odogwu, Director, Alliance Research Institute
Get in touch. Let us know how we can help achieve your goals.
